CRISPR Immune Cells Thrive After Infusion Into Patients

CRISPR Immune Cells Thrive After Infusion Into Patients
Penn Medicine via AP

Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Abramson Cancer Center of the University of Pennsylvania. The team showed cells removed from patients and brought back into the lab setting were able to kill cancer months after their original manufacturing and infusion.

Read Full Article »
Comment
Show comments Hide Comments

Related Articles